Home/Tharimmune/Randy Milby

RM

Randy Milby

Founder, Chief Executive Officer, Chairman of the Board

Therapeutic Areas

Hepatology Immunology Dermatology

Tharimmune Pipeline

Drug	Indication	Phase
TH104 (buccal nalmefene film)	Chronic pruritus in Primary Biliary Cholangitis (PBC)	Phase 2
TH104	Pruritus associated with Atopic Dermatitis	Preclinical

Leadership Team at Tharimmune

Brendan Cavanagh

Chief Operating Officer and Interim Chief Financial Officer

Dr. Kumaraguruparan (Kumar) Subramanian

Chief Scientific Officer

Dr. James A. Rothman

Independent Director

Dr. Michael G. Gray

Independent Director

Independent Director

View full Tharimmune profile